Pacific Biosciences of California, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. For the quarter, the company reported unaudited preliminary revenue of approximately $27.3 million for its fourth quarter ended December 31, 2022.
Pacific Biosciences of California, Inc.
Equities
PACB
US69404D1081
Advanced Medical Equipment & Technology
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.035 USD | -6.44% |
|
+56.15% | -79.31% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.31% | 592M | |
+4.77% | 212B | |
+9.08% | 187B | |
+27.95% | 155B | |
+34.15% | 115B | |
+2.17% | 65.5B | |
+14.28% | 52.87B | |
-3.30% | 45.25B | |
-3.41% | 39.7B | |
+6.41% | 37.72B |
- Stock Market
- Equities
- PACB Stock
- News Pacific Biosciences of California, Inc.
- Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022